Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Payables (2016 - 2025)

VYNE Therapeutics filings provide 10 years of Payables readings, the most recent being $1.0 million for Q4 2025.

  • On a quarterly basis, Payables fell 61.54% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 61.54% decrease, with the full-year FY2025 number at $1.0 million, down 61.54% from a year prior.
  • Payables hit $1.0 million in Q4 2025 for VYNE Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $10.1 million in Q2 2021 to a low of $716000.0 in Q3 2023.
  • Median Payables over the past 5 years was $2.7 million (2024), compared with a mean of $3.3 million.
  • Biggest five-year swings in Payables: plummeted 85.8% in 2022 and later skyrocketed 456.7% in 2024.
  • VYNE Therapeutics' Payables stood at $6.5 million in 2021, then plummeted by 63.35% to $2.4 million in 2022, then tumbled by 30.47% to $1.7 million in 2023, then soared by 63.17% to $2.7 million in 2024, then tumbled by 61.54% to $1.0 million in 2025.
  • The last three reported values for Payables were $1.0 million (Q4 2025), $1.4 million (Q2 2025), and $3.5 million (Q1 2025) per Business Quant data.